Cargando…
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
Autores principales: | Kawano, Satoshi, Grassian, Alexandra R., Tsuda, Masumi, Knutson, Sarah K., Warholic, Natalie M., Kuznetsov, Galina, Xu, Shanqin, Xiao, Yonghong, Pollock, Roy M., Smith, Jesse J., Kuntz, Kevin W., Ribich, Scott, Minoshima, Yukinori, Matsui, Junji, Copeland, Robert A., Tanaka, Shinya, Keilhack, Heike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234811/ https://www.ncbi.nlm.nih.gov/pubmed/28085948 http://dx.doi.org/10.1371/journal.pone.0170539 |
Ejemplares similares
-
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
por: Kawano, Satoshi, et al.
Publicado: (2016) -
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor
with Robust in Vivo Activity
por: Campbell, John E., et al.
Publicado: (2015) -
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
por: Knutson, Sarah K., et al.
Publicado: (2014) -
A Medium-Throughput Single Cell CRISPR-Cas9 Assay to Assess Gene Essentiality
por: Grassian, A. R., et al.
Publicado: (2015) -
Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
por: Ichikawa, Kenji, et al.
Publicado: (2020)